

## Introduction to Triple-Negative Breast Cancer

Citation	Address
Dyck L, Mills KHG. Immune checkpoints and their inhibition in cancer and infectious diseases. <i>Eur J Immunol.</i> 2017;47(5):765-779.	<a href="https://onlinelibrary.wiley.com/doi/full/10.1002/eji.201646875">https://onlinelibrary.wiley.com/doi/full/10.1002/eji.201646875</a>
SEER Cancer Stat Facts: Female Breast Cancer Subtypes. National Cancer Institute. Bethesda, MD. Accessed September 11, 2020.	<a href="https://seer.cancer.gov/statfacts/html/breast-subtypes.html">https://seer.cancer.gov/statfacts/html/breast-subtypes.html</a>
Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. <i>N Engl J Med.</i> 2010;363(20):1938-1948.	<a href="https://www.nejm.org/doi/10.1056/NEJMra1001389">https://www.nejm.org/doi/10.1056/NEJMra1001389</a>
Hammond MEH, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. <i>J Clin Oncol.</i> 2010;28(16):2784-2795.	<a href="https://ascopubs.org/doi/10.1200/JCO.2009.25.6529">https://ascopubs.org/doi/10.1200/JCO.2009.25.6529</a>
Prat A, Adamo B, Cheang MCU, Anders CK, Carey LA, Perou CM. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. <i>Oncologist.</i> 2013;18(2):123-133.	<a href="https://theoncologist.onlinelibrary.wiley.com/doi/full/10.1634/theoncologist.2012-0397">https://theoncologist.onlinelibrary.wiley.com/doi/full/10.1634/theoncologist.2012-0397</a>
Stanton SE, Adams S, Disis ML. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: A systematic review. <i>JAMA Oncol.</i> 2016;2(10):1354-1360.	<a href="https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2016.1061">https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2016.1061</a>
American Cancer Society. Types of Breast Cancer. Triple-negative Breast Cancer. Revised September 20, 2019.	<a href="https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/types-of-breast-cancer/triple-negative.html">https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/types-of-breast-cancer/triple-negative.html</a>
Wolff AC, Hammond MEH, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. <i>J Clin Oncol.</i> 2018;36(20):2105-2122.	<a href="https://ascopubs.org/doi/10.1200/JCO.2018.77.8738">https://ascopubs.org/doi/10.1200/JCO.2018.77.8738</a>

## Combination Therapies for Metastatic TNBC

Citation	Address
Adams S, Loi S, Toppmeyer D, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study. <i>Ann Oncol</i> . 2019;30(3):405-411.	<a href="https://www.annalsofoncology.org/article/S0923-7534(19)31076-2/fulltext">https://www.annalsofoncology.org/article/S0923-7534(19)31076-2/fulltext</a>
Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086 study. <i>Ann Oncol</i> . 2019;30(3):397-404.	<a href="https://www.annalsofoncology.org/article/S0923-7534(19)31075-0/fulltext">https://www.annalsofoncology.org/article/S0923-7534(19)31075-0/fulltext</a>
Cortes J, Cescon DW, Rugo HS. KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. <i>J Clin Oncol</i> . 2020;38(15 suppl):1000.	<a href="https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.1000">https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.1000</a>
Cortes J, Lipatov O, Im S-A, et al. KEYNOTE-119: phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple-negative breast cancer (mTNBC). <i>Ann Oncol</i> . 2019;30(suppl 5):v851-v934.	<a href="https://www.annalsofoncology.org/article/S0923-7534(19)60370-4/pdf">https://www.annalsofoncology.org/article/S0923-7534(19)60370-4/pdf</a>
Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. <i>Clin Cancer Res</i> . 2007;13(15):4429-4434.	<a href="https://clincancerres.aacrjournals.org/content/13/15/4429">https://clincancerres.aacrjournals.org/content/13/15/4429</a>
Economopoulou P, Agelaki S, Perisanidis C, Giotakis EI, Psyrri A. The promise of immunotherapy in head and neck squamous cell carcinoma. <i>Ann Oncol</i> . 2016;27(9):1675-1685.	<a href="https://www.annalsofoncology.org/article/S0923-7534(19)35863-6/fulltext">https://www.annalsofoncology.org/article/S0923-7534(19)35863-6/fulltext</a>
Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: A phase 1 study. <i>JAMA Oncol</i> . 2019;5(1):74-82.	<a href="https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2018.4224">https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2018.4224</a>
Emens LA, Loi S, Rugo HS, et al. Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naïve, locally	<a href="https://cancerres.aacrjournals.org/content/79/4_Supplement/GS1-04">https://cancerres.aacrjournals.org/content/79/4_Supplement/GS1-04</a>

<p>advanced or metastatic triple-negative breast cancer. <i>Cancer Res.</i> 2019;79(4 suppl):GS1-04.</p>	
<p>Furlow B. Pembrolizumab does not prolong survival compared with chemotherapy in metastatic TNBC. <i>Cancer Therapy Advisor.</i> Published September 29, 2019.</p>	<p><a href="https://www.cancertherapyadvisor.com/home/news/conference-coverage/european-society-for-medical-oncology-esmo/esmo-2019/breast-cancer-tnbc-pembrolizumab-does-not-prolong-survival/">https://www.cancertherapyadvisor.com/home/news/conference-coverage/european-society-for-medical-oncology-esmo/esmo-2019/breast-cancer-tnbc-pembrolizumab-does-not-prolong-survival/</a></p>
<p>Gianni L, Huang CS, Egle D, et al. Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. <i>Cancer Res.</i> 2020;80(4 suppl):GS3-04.</p>	<p><a href="https://cancerres.aacrjournals.org/content/80/4_Supplement/GS3-04">https://cancerres.aacrjournals.org/content/80/4_Supplement/GS3-04</a></p>
<p>Gianni L, Huang CS, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer, NeoTRIPaPDL1 Michelangelo randomized study. Slides Presented at 42<sup>nd</sup> Annual San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, TX. <i>Onko News.</i> 2019.</p>	<p><a href="http://www.kongresshighlights.com/uploads/media/SABCS19%20%20Prof.%20Jackisch%20%20Gianni.pdf">http://www.kongresshighlights.com/uploads/media/SABCS19%20%20Prof.%20Jackisch%20%20Gianni.pdf</a></p>
<p>Nanda R, Chow LQM, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 study. <i>J Clin Oncol.</i> 2016;34(21):2460-2467.</p>	<p><a href="https://ascopubs.org/doi/10.1200/JCO.2015.64.8931">https://ascopubs.org/doi/10.1200/JCO.2015.64.8931</a></p>
<p>Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: An analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. <i>JAMA Oncol.</i> 2020;6(5):676-684.</p>	<p><a href="https://jamanetwork.com/journals/jamaoncology/article-abstract/2761193">https://jamanetwork.com/journals/jamaoncology/article-abstract/2761193</a></p>
<p>Nanda R, Liu MC, Yau C, et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. <i>J Clin Oncol.</i> 2017;35(15 Suppl):506.</p>	<p><a href="https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.506">https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.506</a></p>
<p>Pfirschke C, Engblom C, Rickelt S, et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. <i>Immunity.</i> 2016;44(2):343-354.</p>	<p><a href="https://www.cell.com/immunity/fulltext/S1074-7613(16)000339">https://www.cell.com/immunity/fulltext/S1074-7613(16)000339</a></p>

<p>Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. <i>N Engl J Med</i>. 2018;379(22):2108-2121.</p>	<p><a href="https://www.nejm.org/doi/10.1056/NEJMoa1809615">https://www.nejm.org/doi/10.1056/NEJMoa1809615</a></p>
<p>Schmid P, Adams S, Rugo HS, et al. IMpassion130: Results from a global, randomised, double-blind, phase 3 study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC). <i>Ann Oncol</i>. 2018;29(suppl 8):VIII707-VIII708.</p>	<p><a href="https://www.annalsofoncology.org/article/S0923-7534(19)50399-4/fulltext">https://www.annalsofoncology.org/article/S0923-7534(19)50399-4/fulltext</a></p>
<p>Schmid P, Cortes J, Dent R, et al. KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC). <i>Ann of Oncol</i>. 2019;30(suppl 5):V853-V854.</p>	<p><a href="https://www.annalsofoncology.org/article/S0923-7534(19)60363-7/fulltext">https://www.annalsofoncology.org/article/S0923-7534(19)60363-7/fulltext</a></p>
<p>Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. <i>N Engl J Med</i>. 2020;382(9):810-821.</p>	<p><a href="https://www.nejm.org/doi/10.1056/NEJMoa1910549">https://www.nejm.org/doi/10.1056/NEJMoa1910549</a></p>
<p>Schmid P, Cruz C, Braiteh F, et al. Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses. <i>Cancer Res</i>. 2017;77(13 suppl):2986.</p>	<p><a href="https://cancerres.aacrjournals.org/content/77/13_Supplement/2986">https://cancerres.aacrjournals.org/content/77/13_Supplement/2986</a></p>
<p>Schmid P, Park YH, Ferreira M, et al. GS3-03. KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early triple-negative breast cancer: pathologic complete response in key subgroups and by treatment exposure, residual cancer burden, and breast-conserving surgery. Abstract Presented at 42<sup>nd</sup> Annual San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, TX.</p>	<p><a href="https://www.abstractsonline.com/pp8/#!/7946/presentation/2047">https://www.abstractsonline.com/pp8/#!/7946/presentation/2047</a></p>
<p>Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): Updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncol</i>. 2020;21(1):44-59.</p>	<p><a href="https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30689-8/fulltext">https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30689-8/fulltext</a></p>

<p>Schmid P, Salgado R, Park YH, et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: Results from the phase 1b open-label, multicohort KEYNOTE-173 study. <i>Ann Oncol</i>. 2020;31(5):569-581.</p>	<p><a href="https://www.annalsofoncology.org/article/S0923-7534(20)36032-4/fulltext">https://www.annalsofoncology.org/article/S0923-7534(20)36032-4/fulltext</a></p>
<p>Symmans WF, Wei C, Gould R, et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. <i>J Clin Oncol</i>. 2017;35(10):1049-1060.</p>	<p><a href="https://ascopubs.org/doi/10.1200/JCO.2015.63.1010">https://ascopubs.org/doi/10.1200/JCO.2015.63.1010</a></p>

## Side Effects of Immunotherapies in TNBC

Citation	Address
<p>Alhalabi O, Subbiah V. Managing cancer care during the COVID-19 pandemic and beyond. <i>Trends Cancer</i>. 2020;6(7):533-535.</p>	<p><a href="https://www.cell.com/trends/cancer/fulltext/S2405-8033(20)30135-7">https://www.cell.com/trends/cancer/fulltext/S2405-8033(20)30135-7</a></p>
<p>Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. <i>J Clin Oncol</i>. 2018;36(17):1714-1768.</p>	<p><a href="https://ascopubs.org/doi/10.1200/JCO.2017.77.6385">https://ascopubs.org/doi/10.1200/JCO.2017.77.6385</a></p>
<p>Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper. <i>Ann Oncol</i>. 2016;27(4):559-574.</p>	<p><a href="https://www.annalsofoncology.org/article/S0923-7534(19)35750-3/fulltext">https://www.annalsofoncology.org/article/S0923-7534(19)35750-3/fulltext</a></p>
<p>Hu JR, Florido R, Lipson EJ, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. <i>Cardiovasc Res</i>. 2019;115(5):854-868.</p>	<p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452314/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452314/</a></p>
<p>Kottschade L, Brys A, Peikert T, et al. A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. <i>Melanoma Res</i>. 2016;26(5):469-480.</p>	<p><a href="https://journals.lww.com/melanomaresearch/Abstract/2016/10000/A_multidisciplinary_approach_to_toxicity.6.aspx">https://journals.lww.com/melanomaresearch/Abstract/2016/10000/A_multidisciplinary_approach_to_toxicity.6.aspx</a></p>
<p>National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Management of Immunotherapy-Related Toxicities. Version 1.2020.</p>	<p><a href="https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf">https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf</a></p>
<p>Pickwell-Smith BA, So AC, Board RE. Managing side effects of cancer immunotherapy for the acute physician. <i>Br J Hosp Med (Lond)</i>. 2018;79(7):372-377.</p>	<p><a href="https://www.magonlinelibrary.com/doi/abs/10.12968/hmed.2018.79.7.372">https://www.magonlinelibrary.com/doi/abs/10.12968/hmed.2018.79.7.372</a></p>

Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: Skin Toxicities and Immunotherapy. <i>Am J Clin Dermatol</i> . 2018;19(3):345-361.	<a href="https://link.springer.com/article/10.1007%2Fs40257-017-0336-3">https://link.springer.com/article/10.1007%2Fs40257-017-0336-3</a>
Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: Update on management of immune-related toxicities. <i>Transl Lung Cancer Res</i> . 2015;4(5):560-575.	<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630514/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630514/</a>

## The Multidisciplinary Oncology Team

Citation	Address
Agency for Healthcare Research and Quality. Overcoming Barriers to Shared Decision Making. Webinar. Presented May 18, 2015.	<a href="http://www.ahrq.gov/sites/default/files/wysiwyg/professionals/education/curriculum-tools/shareddecisionmaking/webinars/sharewebinar518-slides.pdf">www.ahrq.gov/sites/default/files/wysiwyg/professionals/education/curriculum-tools/shareddecisionmaking/webinars/sharewebinar518-slides.pdf</a>
Bomhof-Roordink H, Fischer MJ, van Duijn-Bakker N, et al. Shared decision making in oncology: A model based on patients', health care professionals', and researchers' views. <i>PsychoOncology</i> . 2019;28(1):139-146.	<a href="https://onlinelibrary.wiley.com/doi/abs/10.1002/pon.4923">https://onlinelibrary.wiley.com/doi/abs/10.1002/pon.4923</a>
National Cancer Institute. NCI Staff. Copanlisib approved for follicular lymphoma[news release]. Published October 16, 2017.	<a href="https://www.cancer.gov/news-events/cancer-currents-blog/2017/aliquopa-fda-follicular-lymphoma">https://www.cancer.gov/news-events/cancer-currents-blog/2017/aliquopa-fda-follicular-lymphoma</a>